fashion -WSS

fashion

author：leisure time 2025-08-19 18:03:35 - browse：1

Monica Bertagnolli -- Health Policy coverage from STAT — Dr. Monica Bertagnolli speaks during a visit from first lady Jill Biden to the University of California San Francisco Helen Diller Family Comprehensive Cancer Center in San Francisco, Friday, Oct. 7, 2022. (AP Photo/Jeff Chiu, Pool) Jeff Chiu/AP

WASHINGTON — Sen. Bernie Sanders (I-Vt.) will hold a confirmation hearing next month for Monica Bertagnolli, President Biden’s nominee to run the National Institutes of Health, he said Friday.

Sanders, whose health committee oversees the confirmation of the NIH nominee, had refused to hold a hearing on Bertagnolli until the Biden administration promised more drug pricing reform.

Newsletters

Sign up for D.C. Diagnosis

An insider's guide to the politics and policies of health care.

Please enter a valid email address. Privacy Policy

HHS announced Friday a deal with Regeneron on the development of the Covid-19 monoclonal antibody. That deal seems to have satisfied Sanders’ demands, though Sanders said the administration must add reasonable pricing provisions to all drugs developed with the help of government funding.

“I welcome the Biden Administration’s announcement today that if Regeneron, through a $326 million contract recently signed with HHS, successfully develops a next generation monoclonal antibody for Covid-19 prevention, the list price of this drug must be equal to or lower than the price in other major countries,” Sanders said in a release.

Sen. Elizabeth Warren (D-Mass.) also had withheld support for Bertagnolli’s nomination until Bertagnolli agreed to Warren’s ethics demands. Bertagnolli agreed to not join the pharmaceutical industry or accept payment from the drug industry, until at least four years after leaving her government position.

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： Patients' immediate access to test results puts radiologists in a bind

WSS

Study points to new risk in gene therapy death of Terry Horgan

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Why sickle cell disease is getting the first CRISPR treatment

Will an HIV vaccine ever be a reality?

Health insurers' Q3 question: how much care are people getting?

The woman behind the Dana Farber

explore

fashion

Sign up for D.C. Diagnosis

knowledge

Medicare details structure of new drug price negotiation program

Leukemia patients are helped by Syndax's new type of therapy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The stability of $0 premiums in Medicare Advantage

Cancer drug shortages should be causing more outrage

STAT letters to the editor on burnt

Drug repurposing or repositioning? The language matters

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Apple is now the first public company to be valued at $3 trillion

IVG is promising — but it won’t replace IVF quite yet

focus

Congenital heart disease patients face new threat of heart failure

Americans' trust in science, scientist continues decline: Report

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Some top drug companies are starting to take action on climate

Study points to new risk in gene therapy death of Terry Horgan

Medicare innovation center doesn’t save money, experts say

knowledge

explore

knowledge

hotspot